【new miniverse lifestyle】Memgen Announces Addition to Board of Directors
HOUSTON / ACCESSWIRE / April 2,new miniverse lifestyle 2020 /
Memgen, a private biotechnology company developing innovative immuno-oncology drugs, announced today that Christopher Pagano has joined the company's Board of Directors.
"I am delighted to join the board of Memgen at this exciting time in the company's development," noted Mr. Pagano. "Memgen is exploiting leading-edge science to develop novel and effective treatments for cancer patients who currently face limited options, and it is gratifying to be able to contribute to moving these products closer to becoming a therapeutic reality."
Dr. Robert Coates, Memgen's Executive Chairman, stated, "We are pleased to be able to attract a professional of Chris's caliber to Memgen, and welcome him to the board. Chris brings his extraordinary experience as a C-Suite financial executive at a Fortune 500 company to Memgen as well his intense interest in biotechnology. We look forward to working closely with him."
Dr. Gregory Brown, Memgen's CEO, also noted, "We are thrilled that Chris has joined the Memgen team, further enriching the leadership capabilities necessary to achieve our mission of delivering novel and effective cancer therapies through the clinic and to patients."
Mr. Pagano has enjoyed a long and successful career, culminating in C-level positions with Assurant, Inc. a NYSE-traded insurance company, where he served successively as Chief Investment Officer, Chief Financial Officer, and Chief Risk Officer over twenty-three years. Previously he served as Portfolio Manager and Head of Fixed Income Asset Management at Assurance Asset Management and became its President and CIO shortly after the company's successful IPO in 2004. He has an MBA from the University of Chicago Graduate School of Business, a BS in Economics from the University of Pennsylvania Wharton School, and has earned the Chartered Financial Analyst (CFA) designation.
About Memgen
Memgen is a cancer immunotherapy company focused on creating drugs that harness the power of the immune system to cure cancer. Its first-in-class immune-oncology therapeutics are designed for the treatment of patients who do not respond to currently available therapeutic options. The Company's lead product, MEM-288, is engineered to both selectively target cancer cells and supercharge the immune system through expression of two unique and powerful immune modulators: CD40 ligand (CD40L) and the powerful cytokine interferon beta. MEM-288 has been demonstrated to generate a strong systemic anti-tumor immune response following intra-tumoral vaccination in multiple tumors. The Company expects to begin clinical testing with MEM-288 in the current year. The Company's pipeline products all utilize its proprietary CD40L transgene, MEM40, which has already been tested in human subjects and has demonstrated the ability to elicit powerful, antigen-specific anti-tumor immune responses across a broad range of tumor types.
Story continues
In this press release, unless the context requires otherwise, "Memgen", the "Company," "Companies," "we," "our," and "us" refers to Memgen, LLC.
Investor Contact:
Gregory B. Brown, M.D.
(203) 940-3742
Media Contacts:
Gregory B. Brown, M.D.
(203) 940-3742
Related Images
SOURCE:
Memgen
View source version on accesswire.com:
https://www.accesswire.com/583459/Memgen-Announces-Addition-to-Board-of-Directors
View comments
下一篇:Donaldson (DCI) Q1 Earnings & Sales Top Estimates, Decline Y/Y
相关文章:
- Why Is Idexx (IDXX) Down 10.3% Since Last Earnings Report?
- Global Care Capital Portfolio Company ViraxClear Secures Supply Contracts to Meet Demand for COVID-19 Antibody Test Kits in Europe and Singapore
- Cytokinetics (CYTK) Reports Q4 Loss, Misses Revenue Estimates
- Meritor to Cut Global Salaried Workers on Coronavirus Scare
- Company News for Mar 10, 2020
- Bank of Montreal: More Upside After a Significant Gain?
- India gold discounts at widest in five months as prices surge
- Brazil manufacturing PMI rises to 38.3 in May from record low 36.0 in April - IHS Markit
- BRIEF-Wangfujing Group, BTG Hotels' Chairman Passed Away Due To Illness
- Albemarle: Q3 Earnings Insights
相关推荐:
- Energy Fuels Inc.'s (TSE:EFR) Intrinsic Value Is Potentially 96% Above Its Share Price
- Hydro66 Announces Additional Advance Under Convertible Loan
- Albemarle: Q3 Earnings Insights
- Ex-Tesla employee agrees to pay $400K over claims he stole trade secrets
- Castlebar Capital Corp. Announces Termination of LOI Respecting Qualifying Transaction
- SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Evolus, Inc. of Class Action Lawsuit and Upcoming Deadline – EOLS
- The Global Enterprise Very Small Aperture Terminal (VSAT) Market is expected to grow by $ 1.82 bn during 2020-2024 progressing at a CAGR of 7% during the forecast period
- State-backed hackers targeting coronavirus workers, US and UK warn
- The Wizz Air Holdings (LON:WIZZ) Share Price Has Gained 160%, So Why Not Pay It Some Attention?
- Why SkiStar AB (publ)'s (STO:SKIS B) High P/E Ratio Isn't Necessarily A Bad Thing
- The Global Military Ground Robot Market is expected to grow by $ 42.08 bn during 2020-2024 progressing at a CAGR of 27% during the forecast period
- Is Husqvarna AB (publ) (STO:HUSQ B) An Attractive Dividend Stock?
- Pinduoduo’s AI strawberry competition offers glimpse of “one-click planting”
- Pan Global Resources Intersects Near Surface Copper Sulphides in New Drill Holes at the Escacena Project, Spain
- Open enrollment 2021: You may be able to carry over unused FSA funds of up to $550
- Coronavirus slows, but doesn't stop real estate lending: Report
- Coronavirus to have substantial impact on trade: WTO
- Coronavirus fears spark 'panic buying' of toilet paper, water, hand sanitizer. Here's why we all need to calm down
- CANADA STOCKS-TSX plunges as coronavirus rout rages
- Monterey Minerals Provides Update on Drill Program